Delivering RNA to target cancer cells more effectively

Targeted RNA delivery using ribonucleoprotein

['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11075133

This study is working on a new way to help deliver special RNA treatments directly to cancer cells, which could make cancer therapies more effective for patients like you.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF WASHINGTON (nih funded)
Locations1 site (SEATTLE, UNITED STATES)
Trial IDNIH-11075133 on ClinicalTrials.gov

What this research studies

This research focuses on improving the delivery of small interfering RNA (siRNA) to cancer cells, which can help silence specific genes involved in cancer progression. The team is developing a novel RNA nanocarrier that utilizes human RNA-binding proteins to enhance the targeting and effectiveness of siRNA therapies. By overcoming challenges related to the delivery of these therapies, the research aims to make antisense therapies more viable for clinical use. Patients may benefit from more effective cancer treatments that utilize this advanced delivery system.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with cancers that could be treated using siRNA therapies.

Not a fit: Patients with cancers that are not amenable to siRNA-based treatments may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective cancer therapies that specifically target and silence harmful genes.

How similar studies have performed: Other research has shown promise in using RNA delivery systems, but this approach is innovative and aims to address longstanding challenges in the field.

Where this research is happening

SEATTLE, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: anti-cancer therapy

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.